Citi reiterates Buy rating on Biohaven Pharma after licensing deal

Go back to Citi reiterates Buy rating on Biohaven Pharma after licensing deal
(NYSE: BHVN) Delayed: 11.75 -0.06 (0.51%)
Previous Close $11.81    52 Week High $ 
Open $11.90    52 Week Low $ 
Day High $12.16    P/E N/A 
Day Low $11.63    EPS $ 
Volume 1,443,718